Application of Single-Cell RNA Sequencing in Pancreatic Cancer and the Endocrine Pancreas

Author(s):  
Qiankun Luo ◽  
Qiang Fu ◽  
Xu Zhang ◽  
Hongwei Zhang ◽  
Tao Qin
2022 ◽  
pp. 101441
Author(s):  
Christian Huisman ◽  
Mason A. Norgard ◽  
Peter R. Levasseur ◽  
Stephanie M. Krasnow ◽  
Monique G.P. van der Wijst ◽  
...  

2022 ◽  
Vol 15 (1) ◽  
pp. 101262
Author(s):  
Jing Zhou ◽  
Yuexu Jiang ◽  
Yue Huang ◽  
Qiongling Wang ◽  
Jussuf T. Kaifi ◽  
...  

Author(s):  
Wojciech J. Szlachcic ◽  
Natalia Ziojla ◽  
Dorota K. Kizewska ◽  
Marcelina Kempa ◽  
Malgorzata Borowiak

A chronic inability to maintain blood glucose homeostasis leads to diabetes, which can damage multiple organs. The pancreatic islets regulate blood glucose levels through the coordinated action of islet cell-secreted hormones, with the insulin released by β-cells playing a crucial role in this process. Diabetes is caused by insufficient insulin secretion due to β-cell loss, or a pancreatic dysfunction. The restoration of a functional β-cell mass might, therefore, offer a cure. To this end, major efforts are underway to generate human β-cells de novo, in vitro, or in vivo. The efficient generation of functional β-cells requires a comprehensive knowledge of pancreas development, including the mechanisms driving cell fate decisions or endocrine cell maturation. Rapid progress in single-cell RNA sequencing (scRNA-Seq) technologies has brought a new dimension to pancreas development research. These methods can capture the transcriptomes of thousands of individual cells, including rare cell types, subtypes, and transient states. With such massive datasets, it is possible to infer the developmental trajectories of cell transitions and gene regulatory pathways. Here, we summarize recent advances in our understanding of endocrine pancreas development and function from scRNA-Seq studies on developing and adult pancreas and human endocrine differentiation models. We also discuss recent scRNA-Seq findings for the pathological pancreas in diabetes, and their implications for better treatment.


2020 ◽  
Author(s):  
Jaewon J. Lee ◽  
Vincent Bernard ◽  
Alexander Semaan ◽  
Maria E. Monberg ◽  
Jonathan Huang ◽  
...  

AbstractPrecision medicine approaches in pancreatic ductal adenocarcinoma (PDAC) are imperative for improving disease outcomes. However, the long-term fidelity of recently deployed ex vivo preclinical platforms, such as patient-derived organoids (PDOs) remains unknown. Through single-cell RNA sequencing (scRNA-seq), we identify substantial transcriptomic evolution of PDOs propagated from the parental tumor, which may alter predicted drug sensitivity. In contrast, scRNA-seq is readily applicable to limited biopsies from human primary and metastatic PDAC and identifies most cancers as being an admixture of previously described epithelial transcriptomic subtypes. Integrative analyses of our data provide an in-depth characterization of the heterogeneity within the tumor microenvironment, including cancer-associated fibroblast (CAF) subclasses, and predicts for a multitude of ligand-receptor interactions, revealing potential targets for immunotherapy approaches. While PDOs continue to enable prospective therapeutic prediction, our analysis also demonstrates the complementarity of using orthogonal de novo biopsies from PDAC patients paired with scRNA-seq to inform clinical decision-making.Statement of SignificanceThe application of single-cell RNA sequencing to diagnostic pancreatic cancer biopsies provides in-depth transcriptomic characterization of the tumor epithelium and microenvironment, while minimizing potential artifacts introduced by an intervening ex vivo passaging step. Thus, this approach can complement the use of patient-derived organoids in implementing precision oncology.


Sign in / Sign up

Export Citation Format

Share Document